The artificial amino acid change in the sialic acid-binding domain of the hemagglutinin neuraminidase of newcastle disease virus increases its specificity to HCT 116 colorectal cancer cells and tumor suppression effect
Tóm tắt
Oncolytic viruses are being studied and developed as novel cancer treatments. Using directed evolution technology, structural modification of the viral surface protein increases the specificity of the oncolytic virus for a particular cancer cell. Newcastle disease virus (NDV) does not show specificity for certain types of cancer cells during infection; therefore, it has low cancer cell specificity. Hemagglutinin is an NDV receptor-binding protein on the cell surface that determines host cell tropism. NDV selectivity for specific cancer cells can be increased by artificial amino acid changes in hemagglutinin neuraminidase HN proteins via directed evolution, leading to improved therapeutic effects. Sialic acid-binding sites (H domains) of the HN protein mutant library were generated using error-prone PCR. Variants of the H domain protein were screened by enzyme-linked immunosorbent assay using HCT 116 cancer cell surface molecules. The mutant S519G H domain protein showed the highest affinity for the surface protein of HCT 116 cells compared to that of different types of cancer cells. This showed that the S519G mutant H domain protein gene replaced the same part of the original HN protein gene, and S519G mutant recombinant NDV (rNDV) was constructed and recovered. S519G rNDV cancer cell killing effects were tested using the MTT assay with various cancer cell types, and the tumor suppression effect of the S519G mutant rNDV was tested in a xenograft mouse model implanted with cancer cells, including HCT 116 cells. S519G rNDV showed increased specificity and enhanced killing ability of HCT 116 cells among various cancer cells and a stronger suppressive effect on tumor growth than the original recombinant NDV. Directed evolution using an artificial amino acid change in the NDV HN (S519G mutant) protein increased its specificity and oncolytic effect in colorectal cancer without changing its virulence. These results provide a new methodology for the use of directed evolution technology for more effective oncolytic virus development.
Tài liệu tham khảo
Siegel RL, Miller KD, Goding Sauer A, Fedewa SA, Butterly LF, Anderson JC, Cercek A, Smith RA, Jemal A. Colorectal cancer statistics, 2020. CA Cancer J Clin. 2020;70:145–64.
Xi Y, Xu P. Global Colorectal cancer burden in 2020 and projections to 2040. Transl Oncol. 2021;14:101174.
Rahman MM, McFadden G. 2021. Oncolytic viruses: newest Frontier for Cancer Immunotherapy. Cancers (Basel) 13.
Fukuhara H, Ino Y, Todo T. Oncolytic virus therapy: a new era of cancer treatment at dawn. Cancer Sci. 2016;107:1373–9.
Kelly E, Russell SJ. History of oncolytic viruses: genesis to genetic engineering. Mol Ther. 2007;15(4):651–9.
Macedo N, Miller DM, Haq R, Kaufman HL. 2020. Clinical landscape of oncolytic virus research in 2020. J Immunother Cancer 8.
Kaufman HL, Kohlhapp FJ, Zloza A. Oncolytic viruses: a new class of immunotherapy Drugs. Nat Rev Drug Discov. 2016;15:660.
Jhawar SR, Thandoni A, Bommareddy PK, Hassan S, Kohlhapp FJ, Goyal S, Schenkel JM, Silk AW, Zloza A. Oncolytic viruses-natural and genetically Engineered Cancer immunotherapies. Front Oncol. 2017;7:202.
Hemminki O, Dos Santos JM, Hemminki A. Oncolytic viruses for cancer immunotherapy. J Hematol Oncol. 2020;13:84.
Huang Z, Guo H, Lin L, Li S, Yang Y, Han Y, et al. Application of oncolytic virus in Tumor therapy. J Med Virol. 2023;95(4):e28729.
Maroun J, Munoz-Alia M, Ammayappan A, Schulze A, Peng KW, Russell S. Designing and building oncolytic viruses. Future Virol. 2017;12:193–213.
Verheije MH, Rottier PJ. Retargeting of viruses to generate oncolytic agents. Adv Virol. 2012;2012:798526.
van den Wollenberg DJ, van den Hengel SK, Dautzenberg IJ, Cramer SJ, Kranenburg O, Hoeben RC. A strategy for genetic modification of the spike-encoding segment of human reovirus T3D for reovirus targeting. Gene Ther. 2008;15:1567–78.
Li L, Liu S, Han D, Tang B, Ma J. Delivery and Biosafety of Oncolytic Virotherapy. Front Oncol. 2020;10:475.
Eager RM, Nemunaitis J. Clinical development directions in oncolytic viral therapy. Cancer Gene Ther. 2011;18:305–17.
Sivanandam V, LaRocca CJ, Chen NG, Fong Y, Warner SG. Oncolytic viruses and Immune Checkpoint Inhibition: the best of both worlds. Mol Ther Oncolytics. 2019;13:93–106.
Moaven O, Mangieri CW, Stauffer JA, Anastasiadis PZ, Borad MJ. 2021. Strategies to develop potent oncolytic viruses and enhance their therapeutic efficacy. JCO Precis Oncol 5.
Rehman H, Silk AW, Kane MP, Kaufman HL. Into the clinic: Talimogene laherparepvec (T-VEC), a first-in-class intratumoral oncolytic viral therapy. J Immunother Cancer. 2016;4:53.
Santos Apolonio J, Lima de Souza Goncalves V, Cordeiro Santos ML, Silva Luz M, Silva Souza JV, Rocha Pinheiro SL, de Souza WR, Sande Loureiro M, de Melo FF. Oncolytic virus therapy in cancer: a current review. World J Virol. 2021;10:229–55.
Excoffon KJ, Koerber JT, Dickey DD, Murtha M, Keshavjee S, Kaspar BK, Zabner J, Schaffer DV. Directed evolution of adeno-associated virus to an infectious respiratory virus. Proc Natl Acad Sci U S A. 2009;106:3865–70.
Bauzon M, Hermiston TW. Oncolytic viruses: the power of directed evolution. Adv Virol. 2012;2012:586389.
Kuhn I, Bauzon M, Green N, Seymour L, Fisher K, Hermiston T. OvAd1, a Novel, Potent, and selective chimeric oncolytic virus developed for Ovarian Cancer by 3D-Directed Evolution. Mol Ther Oncolytics. 2017;4:55–66.
Kuhn I, Harden P, Bauzon M, Chartier C, Nye J, Thorne S, Reid T, Ni S, Lieber A, Fisher K, Seymour L, Rubanyi GM, Harkins RN, Hermiston TW. Directed evolution generates a novel oncolytic virus for the treatment of colon Cancer. PLoS ONE. 2008;3:e2409.
Zainutdinov SS, Kochneva GV, Netesov SV, Chumakov PM, Matveeva OV. Directed evolution as a tool for the selection of oncolytic RNA viruses with desired phenotypes. Oncolytic Virother. 2019;8:9–26.
Zamarin D, Palese P. Oncolytic Newcastle Disease virus for cancer therapy: old challenges and new directions. Future Microbiol. 2012;7:347–67.
Liu T, Zhang Y, Cao Y, Jiang S, Sun R, Yin J, Gao Z, Ren G, Wang Z, Yu Q, Sui G, Sun X, Sun W, Xiao W, Li D. Optimization of oncolytic effect of Newcastle Disease virus Clone30 by selecting sensitive Tumor host and constructing more oncolytic viruses. Gene Ther. 2021;28:697–717.
Cattaneo R, Miest T, Shashkova EV, Barry MA. Reprogrammed viruses as cancer therapeutics: targeted, armed and shielded. Nat Rev Microbiol. 2008;6:529–40.
Fournier P, Bian H, Szeberenyi J, Schirrmacher V. Analysis of three properties of Newcastle Disease virus for fighting cancer: tumor-selective replication, antitumor cytotoxicity, and immunostimulation. Methods Mol Biol. 2012;797:177–204.
Cai Z, Lv H, Cao W, Zhou C, Liu Q, Li H, Zhou F. Targeting strategies of adenovirusmediated gene therapy and virotherapy for Prostate cancer (review). Mol Med Rep. 2017;16:6443–58.
Liu XY, Gu JF. Targeting gene-virotherapy of cancer. Cell Res. 2006;16:25–30.
Meng Q, He J, Zhong L, Zhao Y. Advances in the study of Antitumour Immunotherapy for Newcastle Disease Virus. Int J Med Sci. 2021;18:2294–302.
Goradel NH, Baker AT, Arashkia A, Ebrahimi N, Ghorghanlu S, Negahdari B. Oncolytic virotherapy: challenges and solutions. Curr Probl Cancer. 2021;45:100639.
Schirrmacher V. 2016. Fifty Years of Clinical Application of Newcastle Disease Virus: Time to Celebrate! Biomedicines 4.
Cheng X, Wang W, Xu Q, Harper J, Carroll D, Galinski MS, Suzich J, Jin H. Genetic modification of Oncolytic Newcastle Disease Virus for Cancer Therapy. J Virol. 2016;90:5343–52.
Rabiei M, Low WY, Ren Y, Cahyono MI, Doan PTK, Dharmayanti I, Grande ED, Hemmatzadeh F. Indicators of the molecular pathogenesis of virulent Newcastle Disease virus in chickens revealed by transcriptomic profiling of spleen. Sci Rep. 2021;11:17570.
Yurchenko KS, Zhou P, Kovner AV, Zavjalov EL, Shestopalova LV, Shestopalov AM. Oncolytic effect of wild-type Newcastle Disease virus isolates in cancer cell lines in vitro and in vivo on xenograft model. PLoS ONE. 2018;13:e0195425.
Parede L, Young PL. The pathogenesis of velogenic Newcastle Disease virus Infection of chickens of different ages and different levels of immunity. Avian Dis. 1990;34:803–8.
Huang Z, Panda A, Elankumaran S, Govindarajan D, Rockemann DD, Samal SK. The hemagglutinin-neuraminidase protein of Newcastle Disease virus determines tropism and virulence. J Virol. 2004;78:4176–84.
Tayeb S, Zakay-Rones Z, Panet A. Therapeutic potential of oncolytic Newcastle Disease virus: a critical review. Oncolytic Virother. 2015;4:49–62.
Sanchez-Felipe L, Villar E, Munoz-Barroso I. Entry of Newcastle Disease Virus into the host cell: role of acidic pH and endocytosis. Biochim Biophys Acta. 2014;1838:300–9.
Zaitsev V, von Itzstein M, Groves D, Kiefel M, Takimoto T, Portner A, Taylor G. Second sialic acid binding site in Newcastle Disease virus hemagglutinin-neuraminidase: implications for fusion. J Virol. 2004;78:3733–41.
Crennell S, Takimoto T, Portner A, Taylor G. Crystal structure of the multifunctional paramyxovirus hemagglutinin-neuraminidase. Nat Struct Biol. 2000;7:1068–74.
Yuan P, Swanson KA, Leser GP, Paterson RG, Lamb RA, Jardetzky TS. Structure of the Newcastle Disease virus hemagglutinin-neuraminidase (HN) ectodomain reveals a four-helix bundle stalk. Proc Natl Acad Sci U S A. 2011;108:14920–5.
Xia Y, Li K, Li J, Wang T, Gu L, Xun L. T5 exonuclease-dependent assembly offers a low-cost method for efficient cloning and site-directed mutagenesis. Nucleic Acids Res. 2019;47:e15.
Tan L, Wen G, Qiu X, Yuan Y, Meng C, Sun Y, Liao Y, Song C, Liu W, Shi Y, Shao H, Ding C. 2019. A recombinant La Sota Vaccine strain expressing multiple epitopes of infectious Bronchitis virus (IBV) protects specific Pathogen-Free (SPF) chickens against IBV and NDV challenges. Vaccines (Basel) 7.
Alexander DJ. Newcastle Disease diagnosis. Boston: Kluwer Academic Publisher; 1988. pp. 147–60.
Beard CW, Hopkins SR, Hammond J. Preparation of Newcastle Disease virus hemagglutination-inhibition test antigen. Avian Dis. 1975;19:692–9.
Burke S, Shergold A, Elder MJ, Whitworth J, Cheng X, Jin H, Wilkinson RW, Harper J, Carroll DK. Oncolytic Newcastle Disease virus activation of the innate immune response and priming of antitumor adaptive responses in vitro. Cancer Immunol Immunother. 2020;69:1015–27.
Xu Q, Rangaswamy US, Wang W, Robbins SH, Harper J, Jin H, Cheng X. Evaluation of Newcastle Disease virus mediated dendritic cell activation and cross-priming tumor-specific immune responses ex vivo. Int J Cancer. 2020;146:531–41.
Song D, Jia X, Liu X, Hu L, Lin K, Xiao T, Qiao Y, Zhang J, Dan J, Wong C, Hu C, Sai K, Gong S, Sander M, Shen R, Chen X, Xiao X, Chen J, Zhang Y, Wei C, Liang J, Zhang Q, Hu J, Zhu W, Yan G, Lin Y, Cai J. Identification of the receptor of oncolytic virus M1 as a therapeutic predictor for multiple solid tumors. Signal Transduct Target Ther. 2022;7:100.
Butt SL, Moura V, Susta L, Miller PJ, Hutcheson JM, Cardenas-Garcia S, Brown CC, West FD, Afonso CL, Stanton JB. Tropism of Newcastle Disease virus strains for chicken neurons, astrocytes, oligodendrocytes, and microglia. BMC Vet Res. 2019;15:317.
Khosrowabadi E, Wenta T, Keskitalo S, Manninen A, Kellokumpu S. Altered glycosylation of several metastasis-associated glycoproteins with terminal GalNAc defines the highly invasive cancer cell phenotype. Oncotarget. 2022;13:73–89.
Liu Y, Chi M, Wen H, Zhao L, Song Y, Liu N, Wang Z. Roles of the highly conserved amino acids in the second receptor binding site of the Newcastle Disease virus HN protein. Virol J. 2019;16:164.
Vasserot AP, Dickinson CD, Tang Y, Huse WD, Manchester KS, Watkins JD. Optimization of protein therapeutics by directed evolution. Drug Discov Today. 2003;8:118–26.
Nirantar SR. 2021. Directed evolution methods for enzyme Engineering. Molecules 26.